Bispecific dendritic-T cell engager potentiates anti-tumor immunity

Area of Science:

• Immunology
• Cancer Research
• Biotechnology

Background:

• Immune checkpoint inhibition, particularly anti-PD-1 monoclonal antibodies, represents a significant advancement in cancer immunotherapy.
• However, a substantial proportion of patients exhibit resistance or recurrence, highlighting the need for improved therapeutic strategies.
• The efficacy of anti-PD-1 therapy is closely linked to the intricate crosstalk between conventional type I dendritic cells (cDC1) and T cells within the tumor microenvironment.

Purpose of the Study:

• To investigate the critical role of cDC1 and T cell interactions in mediating effective anti-tumor responses to anti-PD-1 therapy.
• To develop and evaluate a novel therapeutic agent designed to enhance this specific immune cell crosstalk.
• To assess the in vivo efficacy of this new agent in reprogramming anti-tumor immunity compared to conventional treatments.

Main Methods:

• Development of a bispecific DC-T cell engager (BiCE) to facilitate physical interactions between PD-1-expressing T cells and cDC1.
• Analysis of immune cell crosstalk within tumors and tumor-draining lymph nodes following BiCE treatment.
• In vivo assessment using single-cell and physical interacting cell analysis to evaluate immune reprogramming.
• Comparison of BiCE treatment with conventional anti-PD-1 therapy in preclinical models.

Main Results:

• BiCE treatment successfully promoted active dendritic cell and T cell crosstalk in both tumor tissues and draining lymph nodes.
• In vivo analyses revealed that BiCE induced superior and distinct immune reprogramming of tumors and associated lymph nodes compared to standard anti-PD-1 therapy.
• The reagent effectively bridged immune cells, thereby potentiating essential cell circuits and communication pathways critical for anti-tumor immunity.

Conclusions:

• The crosstalk between cDC1 and T cells is indispensable for effective anti-PD-1-mediated anti-tumor immunity.
• Bispecific DC-T cell engagers (BiCE) represent a promising strategy to enhance anti-tumor responses by facilitating this crucial immune cell interaction.
• BiCE offers a novel approach to overcome limitations of current immunotherapies by optimizing immune cell communication for robust anti-cancer effects.